相约AACR丨拿因生物受邀参加壁报展示 2025/04/28 2 P.M.-5 P.M.CST
中国杭州，2025年2月13日 -- 创新肿瘤治疗领域迎来重要突破。专注于破解肿瘤耐药难题的全球领先生物医药企业拿因生物今日宣布，其自主研发的全球首个靶向PDIA6/IRE1蛋白互作的小分子调节剂的临床前研究成果，将于2025年4月25-30日在美国芝加哥举行的美国癌症研究协会（AACR）年会上以壁报形式重磅亮相。该突破性研究为选择性增强肿瘤细胞对内质网应激（ER stress）敏感性、诱导肿瘤产生调节性细胞死亡提供了全新靶点和治疗策略
【研究亮点速览】
壁报主题：Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death（全球首创PDIA6/IRE1蛋白互作调节剂——选择性增强肿瘤细胞内质网应激敏感性及调节性细胞死亡）
会议板块：实验与分子治疗（Experimental and Molecular Therapeutics）
专题研讨：新型抗肿瘤药物研发2（Novel Antitumor Agents 2）
展示时间：2025年4月28日14:00-17:00（美国中部时间）
学术坐标：21号展区14号壁报（摘要编号：3045）
作为全球历史最悠久、规模最大的肿瘤学术盛会，AACR年会历来是检验创新药物研发实力的试金石。此次研究成果的入选，不仅印证了拿因生物在肿瘤耐药领域的源头创新能力，更彰显了该候选药物显著的临床转化价值。公司研发团队通过精准调控内质网应激通路，开辟了克服肿瘤耐药的全新治疗维度。
关于拿因生物
拿因生物于2020年12月正式成立，其科学家团队从全新药靶等生物学源头开启探索，运用基于协同致死的联合治疗等前沿策略，全力攻克肿瘤耐药复发等关键瓶颈问题，积极研发肿瘤干细胞分化诱导剂和调节性细胞死亡诱导剂等创新药物。拿因生物始终以满足未被满足的临床需求为使命，期望为广大患者带来显著的临床获益。
Nain Biotech will present preclinical research data for a small molecule PDIA6/IRE1 modulator at the AACR Annual Meeting 2025
Hangzhou, China, February 13, 2025 -- Nain Biotech, a global first-in-class drug discovery company focusing on cancer drug resistance, today announced that it will present a poster about preclinical research results of its first-in-class small molecule PDIA6/IRE1 modulator at the American Association for Cancer Research (AACR) Annual Meeting 2025.
Details of the poster presentation are as follows:
Poster Title: Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 2
Session Start: 4/28/2025 2:00:00 PM
Session End: 4/28/2025 5:00:00 PM
Location: Poster Section 21
Poster Board Number: 14
Published Abstract Number: 3045
The AACR Annual Meeting 2025 will be held from April 25 to 30, 2025, in Chicago, USA. As one of the oldest and largest academic conferences on cancer research globally, the AACR Annual Meeting brings together the most cutting-edge research findings in the field of oncology. The inclusion of the company's research project in the AACR signifies recognition of the company's innovative capabilities and the clinical potential of its products.
About Nain Biotech
Nain Biotech was founded in December 2020. Nain focuses on developing novel CSC and RCD modulators, finding novel drug targets, and tackling drug resistance in cancer. Nain's team of scientists, by targeting drug resistance for cancer eradication, are hoping to bring significant clinical benefits to patients and committed to addressing unmet clinical needs.
